Locations and Appointments
- Urological Oncology
- Prostate Cancer
- Bladder Cancer
- Genitourinary Surgery
- Kidney Cancer
- Testicular Cancer
- Urologic Cancer
Clinical & Academic Positions
- Attending Urologist - NewYork-Presbyterian Hospital
- Professor of Urology - Weill Cornell Medical College, Cornell University
Education & Training
- M.D., George Washington University School of Medicine and Health Sciences, 1994
Urologic oncology is a multidisciplinary field that incorporates innovative surgical technology, systemic treatments such as chemotherapy as well as a focused research effort. As a Professor of Urology and the Clinical Director of Urologic Oncology I continually interact with colleagues in areas of medical oncology, radiation oncology, pathology among others in order to provide the most comprehensive and innovative care for our patients with prostate, bladder, kidney and testicular cancer. Advances in robotic technology along with scientific progress in our precision medicine program have allowed us to direct therapy in unprecedented ways. As a leader in this area I look forward to continued advances in this exciting and challenging field.
For more information on Dr. Scherr, please CLICK HERE.
Dr. Douglas Scherr is a Professor of Urology and the Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University in New York City.
Dr. Scherr received his undergraduate degree in Government at Cornell University. After a year teaching English in Shenyang, China, Dr. Scherr completed his medical training at The George Washington University School of Medicine in Washington, D.C. Following this he completed a 6 year residency in Urology at The New York Hospital-Cornell University Medical Center. Subsequently, Dr. Scherr then went on to pursue a Fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York for two years. Beginning in 2001, Dr. Scherr has been on the full time faculty in the Department of Urology at Cornell where he has his current appointment. Dr. Scherr also holds an appointment at the Rockefeller University in New York.
Dr. Scherr’s clinical focus is in the treatment of urologic malignancies. In particular, the treatment of prostate cancer, bladder cancer, kidney cancer, and testicular cancers, as well as genitourinary and retroperitoneal sarcomas. Dr. Scherr was the first physician at Cornell to perform a robotic prostatectomy, and he has since performed hundreds of these procedures and travels nationally and internationally teaching the procedure to many urologic surgeons. Dr. Scherr has expanded his robotic practice in Manhattan to now include robotic-assisted removal of bladders with total bladder reconstructions. Dr. Scherr has published extensively in the areas of bladder and prostate cancer as well a wide variety of other urologic malignancies.
In addition to his clinical responsibilities, Dr. Scherr also has an active role in the Laboratory of Urologic Oncology. Dr. Scherr has been instrumental in defining the hormonal regulation of bladder cancer and is now developing a novel class of compounds that utilize the innate immune system to fight urologic tumors. From a technology front, Dr. Scherr is currently working on the development of a non-invasive means to assess human tissue at the microscopic level. To this end, he has patented and developed the concept of “multiphoton endoscopy,” which utilizes high speed laser energy to create high quality microscopic images of human tissue. This breakthrough has vast applications in cystoscopy, colonoscopy and bronchoscopy among others. Dr. Scherr is collaborating with engineers and physicists at Cornell University in Ithaca, New York on this project.
Dr. Scherr sits on several advisory boards in companies involved in urologic technology development. In particular, Dr. Scherr has been influential in the ergonomics of robotic technology. In addition, he has been quite active in the development of optical coherence tomography and its application to urologic imaging. Dr. Scherr collaborates with many scientists within the Weill Cornell community and is currently evaluating the role of adipose inflammation and cancer as well as the functional role of the intestinal microbiome and prostate cancer. Dr. Scherr is married with three children and resides in Westchester, NY.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA - HMO
- AETNA - PPO
- AETNA - Medicare
- Aetna - Weill Cornell - POS
- Aetna-NYP - EPO/POS
- Empire Blue Cross/Blue Shield - Mediblue (Senior)
- Empire Blue Cross/Blue Shield - PPO
- Empire Blue Cross/Blue Shield - HMO
- Empire Blue Cross/Blue Shield - EPO
- Empire Empire Blue Cross/Blue Shield HealthPlus - CHP
- Empire Empire Blue Cross/Blue Shield HealthPlus
- GHI - CBP
- Health Insurance Plan of NY (HIP) - Medicare
- Health Insurance Plan of NY (HIP)
- Oxford Health Plans - Metro/Core/Charter
- Oxford Health Plans - Medicare Advantage
- Oxford Health Plans - Liberty
- Oxford Health Plans - Freedom
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care - Medicare
- United Health Care
Honors and Awards
Honors and Awards
William Beaumont Medical Research Honor Society
First Prize for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. crisis of unknown proportion: An empirical analysis of the American medical malpractice system. 1994
First Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, "BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy." 1998
First Prize for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. "Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES." 2000
Second Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, "Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbesterol (DES)." 2000
Pfizer, Scholars in Urology Award, Awarded for advancing the scientific and clinical field of urology. 2000
Ferdinand C. Valentine Fellowship for Research in Urology. The New York Academy of Medicine. 2001-2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.
T32 Research Training Grant. Memorial Sloan Kettering Cancer Center. 2000-2002.
Edwin Beer Research Award. NY Academy of Medicine. Effective Tumor Immunotherapy in Transitional Cell Carcinoma of the Bladder. 2004-2006
Career Development Award. Kidney Urology Foundation of America. The role of the Pim-1 Oncoprotein in Prostate Carcinogenesis. 2004-2005